Abstract: Provided herein are isotopically labeled reagents, including isotopically labeled small molecules and peptides, that can be used to detect and/or quantify ?-N-methylamino-L-alanine (BMAA) in a sample. The reagents can be used as stable isotope labeled standards in analytical methods, including in conjunction with mass spectrometry, to detect and/or quantify BMAA in a sample, such as a protein sample from a subject.

Abstract: Provided herein are isotopically labeled reagents, including isotopically labeled small molecules and peptides, that can be used to detect and/or quantify ?-N-methylamino-L-alanine (BMAA) in the Cu/Zn Superoxide Dismutase 1 (SOD1) protein. Further provided are methods for detecting, preventing, or treating amyotrophic lateral sclerosis in a subject using isotopically labeled reagents to detect and/or quantify ?-N-methylamino-L-alanine (BMAA) in the Cu/Zn Superoxide Dismutase 1 (50D1) protein. Further provided are isotopically labeled reagents and methods for detecting BMAA in additional proteins from patient samples.

Abstract: Provided herein are isotopically labeled reagents, including isotopically labeled small molecules and peptides, that can be used to detect and/or quantify ?-N-methylamino-L-alanine (BMAA) in a sample. The reagents can be used as stable isotope labeled standards in analytical methods, including in conjunction with mass spectrometry, to detect and/or quantify BMAA in a sample, such as a protein sample from a subject.

Abstract: A preparation of peptides eluted from class II HLA molecules is disclosed. Methods of decreasing measles infections comprising inoculating human patients with a vaccine comprising one or more of the peptides and methods of diagnosing measles infections or immunity comprising analyzing human patients for the presence of one or more of the peptides or antibodies to the peptide(s) are also disclosed.

Abstract: A preparation of peptides eluted from class II HLA molecules is disclosed. Methods of decreasing measles infections comprising inoculating human patients with a vaccine comprising one or more of the peptides and methods of diagnosing measles infections or immunity comprising analyzing human patients for the presence of one or more of the peptides or antibodies to the peptide(s) are also disclosed.

Abstract: A vaccine for preventing or treating Orthopoxvirus infection that induces a protective or therapeutic immune response, wherein the vaccine comprises (1) an amino acid sequence of 20 amino acid or less (preferably 12 amino acid or less and most preferably 11 amino acid or less) of the formula X1-SEQ ID NO:1-X2, wherein X1 and X2 are peptides of 0-11 amino acid in length comprising either native or non-native amino acid sequences, (2) an antigen-presenting cell pulsed with the peptide, or (3) a cell sensitized in vitro to the peptide is disclosed.

Abstract: A preparation of peptides eluted from class II HLA molecules is disclosed. Methods of decreasing measles infections comprising inoculating human patients with a vaccine comprising one or more of the peptides and methods of diagnosing measles infections or immunity comprising analyzing human patients for the presence of one or more of the peptides or antibodies to the peptide(s) are also disclosed.

Abstract: A dual electrospray ionization source for use in connection with a mass spectrometer having an inlet port. The source includes a polymer nozzle holder having a drive axis and a pair of continuously spraying nozzles mounted to the nozzle holder at spaced-apart positions. An adjustment mechanism allows positional adjustment of one nozzle with respect to the other nozzle on the nozzle holder. A programmable motor is connected to the nozzle holder at the drive axis. The motor rotationally and reciprocally drives the nozzle holder to sequentially position each of the nozzles in alignment with an inlet port of mass spectrometer.